1. Introduction {#sec1}
===============

The severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) initially emerged in Wuhan, Hubei, People\'s Republic of China and has been identified as the causative agent of coronavirus disease 2019 (COVID-19). It\'s pandemic spread presents a substantial medical challenge with an enormous societal and economic toll \[[@bib1],[@bib2]\]. Similar to influenza and SARS-CoV-1, SARS-CoV-2 is considered a "crowd disease" that spreads most easily when individuals are packed together at high densities. Phylogenetic data implicate a zoonotic origin \[[@bib3]\] and the rapid spread suggests ongoing person-to-person transmission \[[@bib4]\]. Additional factors contributing to the rapid spread constitute the duration of the incubation period \[[@bib5]\] and infectiousness peaking on or before symptom onset \[[@bib6]\] contribute to the rapid spread of SARS-CoV-2. Another factor contributing to the rapid spread and alarmingly high number of infected people is the SARS-CoV-2 nature of initial dormancy of symptoms. The most common symptoms associated with COVID-19 include a sudden onset of fever, coughing, and dyspnea \[[@bib2],[@bib7],[@bib8]\]. Complications comprise acute respiratory distress syndrome (ARDS), pneumonia, kidney failure, bacterial superinfections, coagulation abnormalities and thromboembolic events, sepsis, and even death \[[@bib9],[@bib10]\]. So far, only a few demographic and clinical factors, such as older age, diabetes, and cardiovascular diseases, have been linked with poor outcome and increased risk of mortality \[[@bib11],[@bib12]\]. This knowledge gap extends to the risk of infections, disease progression, and outcomes in vulnerable patient populations, including newborns, children, pregnant, and elderly patients. A better understanding of the risks for these vulnerable patient populations is critical in order to optimize their protection and tailor prevention and treatment strategies. Thus, the aim of our systematic review and meta-analysis was to gather available information in the literature and determine the most prevalent comorbidities, clinical signs and symptoms, imaging features, laboratory parameters, treatments, outcomes, and complications arising in patients with COVID-19. We stratified our systematic reviews and meta-analysis by different cohorts, namely pediatric/neonatal and adult COVID-19 patients including pregnant women. Furthermore, we aimed to assess current evidence for the associations between risk factors and in-hospital mortality. Based on previous reports, we addressed the hypothesis that male sex, older age, as well as pre-existing hypertension and diabetes mellitus are risk factors of morbidity and mortality in patients with COVID-19.

2. Methods {#sec2}
==========

Our systematic review and meta-analysis adhere to the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) statement \[[@bib13]\] and Meta-analysis of Observational Studies in Epidemiology (MOOSE) checklist \[[@bib14]\].

2.1. Search strategy and selection criteria {#sec2.1}
-------------------------------------------

Four bibliographic databases were systematically searched: EMBASE, PubMed/Medline, Scopus, and Web of Science. Our search was not restricted by language. We searched for studies published from December 1st, 2019 to March 28th, 2020, with search terms related to COVID-19 ("COVID-19", "SARS-CoV-2", "coronavirus disease 2019", "severe acute respiratory syndrome coronavirus 2", "2019 novel coronavirus", "2019-nCoV", "coronavirus", and "corona virus"). The full search strategy is provided in [Appendix 1](#appsec1){ref-type="sec"}. Manual searching was also performed, reviewing reference lists of relevant studies and comprehensive review articles. Records were managed by EndNote X 8.0 software to exclude duplicates.

2.2. Selection of studies {#sec2.2}
-------------------------

Two investigators (CRJ and MW) independently screened the titles and abstracts to determine whether studies should be included. Eligibility criteria were also applied to the full-text articles during the final selection. In case multiple articles reported on a single study, the article that provided the most data was selected for further synthesis. We quantified the inter-rater agreement for study selection using Cohen\'s *κ* coefficient \[[@bib15]\]. Articles written in Chinese were reviewed by our two native speaking authors (BT and CW) and if the inclusion criteria were met, these authors also extracted the specified data. All disagreements were discussed and resolved at a consensus meeting.

2.3. Inclusion and exclusion criteria {#sec2.3}
-------------------------------------

All full-text, peer-reviewed articles that described case-control, cohort studies, or case studies investigating the epidemiological and clinical features, comorbidities, laboratory parameters, imaging features, treatment, and/or outcomes (e.g., death) of patients that were diagnosed with COVID-19. We excluded duplicate publications, non-peer reviewed articles (e.g., preprints), reviews, meta-analyses, abstracts or conference proceedings, editorials, commentaries, letters with insufficient data, studies on non-human species, or out-of-scope studies (e.g., comparison with other infections, case-fatality reports). In case multiple studies published data from the same cohort, we included the article representing the most inclusive information on the population to avoid overlap. Lastly, studies that did not report demographics (i.e., age and sex) were also excluded. [Fig. 1](#fig1){ref-type="fig"} outlines our search strategy and application of inclusion and exclusion criteria.Fig. 1Flow-chart of the search strategy. A total of 148 studies were eligible for the literature review and the first part of the meta-analysis (i.e., prevalence). Nineteen studies were included in the second part of the meta-analysis (i.e., severity and mortality).Fig. 1

2.4. Data extraction and synthesis {#sec2.4}
----------------------------------

Data extraction tables were created with the following information: 1) publication information (i.e., author, date, language of article, country where the study was performed, study design \[case study, case series, or cohort study\] \[[@bib16]\], study population \[pediatric/neonatal and adult COVID-19 patients including pregnant women); 2) demographics (i.e., age, sex); 3) clinical signs and symptoms (e.g., cough, fatigue, fever, sputum); 3) comorbidities (e.g., hypertension, diabetes, cardiovascular diseases); 4) therapies administered to treat COVID-19 (e.g., antibiotics, antivirals, invasive mechanical ventilation); 5) clinical outcomes (e.g., death, survival, recovery); and 6) complications associated with COVID-19 (e.g., sepsis and shock, ARDS). In case studies provided data for multiple patient groups (e.g., pediatric and adult patient), we extracted this information separately for each group. A full list of extracted variables is provided in [Supplementary Table 1](#appsec1){ref-type="sec"}.

2.5. Statistical analysis {#sec2.5}
-------------------------

For the studies reporting mean and standard deviation (SD) for extracted variables, we computed the median and interquartile ranges (IQR) assuming a normal distribution (i.e., using the formula: IQR \~SD\*1.35). To test if there is a bias by including the studies for which we computed the median and IQR (i.e., quartiles, Q1 and Q3), we performed a sensitivity analyses in which we calculated the median and IQR under the assumption of right-skewed and left-skewed distribution (see [Appendix 2](#appsec1){ref-type="sec"}). We compared the results of the different distributions to test the robustness of our findings. Descriptive statistics (median, IQR, n, and %) were used to characterize the studies and patients included as well as the laboratory parameters. Weighted by study sample size, the pooled median and 95% confidence interval (CI) were computed for continuous variables. Normality approximation of the binomial was used to construct an approximate confidence interval (R package *metamedian* \[[@bib17]\]). Welch\'s two-sample *t*-test was employed to test if there are significant differences in the proportion of male and female patients across studies.

Our meta-analysis was structured in two parts. In the first part, we performed meta-analyses of all 148 studies to define the prevalence of comorbidities, clinical signs and symptoms, imaging features, treatments, outcomes, and complications associated with COVID-19. Using the *metaprop* function of the R package *metafor* \[[@bib18]\], we calculated the overall prevalence from studies reporting a single prevalence. Our meta-analysis was stratified by patient group (pediatric/neonatal \[≤17 years of age\], pregnant, and adult COVID-19 patients). Heterogeneity between studies was assessed visually by Forest plots, and analytically by *I* ^*2*^, Tau (*T* ^2^), and Cochrane Q. Briefly put, *I* ^2^ describes the percentage of variation across studies that is due to heterogeneity rather than chance \[[@bib19]\]: 0% indicates no heterogeneity, whereas 25%, 50%, and 75% indicate low, moderate, and high heterogeneity, respectively. The CIs for *I* ^2^ were calculated using the iterative non-central chi-squared distribution method of Hedges and Piggott \[[@bib20]\]. Tau (*T* ^2^ *)* represents the absolute value of the true variance (heterogeneity) and is the estimated SD of underlying true effects across studies. Cochran\'s Q is the weighted sum of squared differences between individual study effects and the pooled effect across studies, with the weights being those used in the pooling method (i.e., sample size) \[[@bib21]\]. The second part comprised meta-analyses to calculate the relative risk (RR) of certain comorbidities, clinical signs and symptoms, imaging features, laboratory parameters, complications, and outcomes in patients with severe vs. those with non-severe disease condition (12 studies) as well as deceased vs. survivors (7 studies). The categorization into severe and non-severe COVID-19 disease was consistent with the groups reported by the reviewed studies ([Supplementary Table 2](#appsec1){ref-type="sec"}). Owing to our judgment that considerable clinical and statistical heterogeneity exists among the studies (statistical heterogeneity was confirmed by the computed *I* ^2^ *,* *T* ^2^, and Cochrane Q), we calculated pooled RRs with 95% CIs using random-effects models with inverse-variance weighting (*metabin* function from R package *meta*). For continuous outcome data (e.g., age, laboratory parameters, and time from symptoms onset to hospital admission), we estimated the standardized mean difference (SMD) by means of a random-effects models with inverse variance weighting for pooling (*metacont* function from R package meta). To calculate the SMD, we converted medians, Q1s, and Q3s into means and standard deviations. The SMD, 95% CIs, and p values were reported. We produced Forest plots to visualize the results from the random-effects models (R function: *forest*). Publication bias was assessed visually by funnel plots (R function: *funnel*) and analytically by the Egger test (R function: *regtest*). An Egger test p \< 0.05 indicates a significant publication bias. All statistical analyses were performed in R (version 3.6.3) for MacOS X (Mojave, 10.14.4) with the packages meta (version 4.11--0) and *dmetar* (version 0.0.90) \[[@bib18]\]. The code used for the analysis and to create figures and tables is provided in our GitHub repository (<https://github.com/jutzca/Corona-Virus-Meta-Analysis-2020>).

2.6. Role of funding source {#sec2.6}
---------------------------

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

3. Results {#sec3}
==========

3.1. Study selection and study characteristics {#sec3.1}
----------------------------------------------

Our systematic literature search yielded 5′049 articles (including articles identified by manual searching). Upon removal of duplicates and exclusion of studies on the basis of their abstracts or following screening their full text, 148 met the inclusion criteria and were considered for the review and meta-analysis ([Fig. 1](#fig1){ref-type="fig"}) \[[@bib4],[@bib8],[@bib9],[@bib11],[@bib22], [@bib165]\]. The inter-rater agreement for study selection was very high (κ = 0.94 \[95% CI: 0.91--0.96\], 97.0% agreement \[11/362 studies with disagreement\]). Detailed information on the included studies are provided in [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"} . Included studies were conducted in 15 countries between December 1st, 2019 and March 28th, 2020 ([Supplementary Table 3](#appsec1){ref-type="sec"}) and enrolled between 1 and 1′099 patients (median 12.5 \[1.00--56.75\]). The majority of the articles were written in English (123 studies, 83.1%) and the remainder in Chinese (25 studies, 16.9%). We classified studies according to their design \[[@bib16]\]: cohort study (76 studies, 51.4%), case study/report (41 studies, 27.7%), and case series (31 studies, 20.9%). While all studies reported information on demographics (148, 100%), the number of studies reporting information on comorbidities (84 studies, 56.8%), clinical sign and symptoms (130 studies, 87.8%), laboratory parameters (113 studies, 76.4%), imaging features (118 studies, 79.7%), treatments (91, 61.5%), outcomes (118 studies, 79.3%), and complications (59 studies, 39.9%) varied markedly.Table 1Included studies of adults with COVID-19.Table 1AuthorsTitlePMIDUnique study IDCountryLanguageStudy typeStudy populationSample sizeAge[a](#tbl1fna){ref-type="table-fn"}Male (%)Female (%)Ai et al., 2020 \[[@bib32]\]Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases[32101510](pmid:32101510){#intref0035}S1ChinaEnglishCohort StudyAdult101451 (15)467 (46)547 (54)Albarello et al., 2020 \[[@bib159]\]2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation[32112966](pmid:32112966){#intref0040}S2ItalyEnglishCase seriesAdult266.5 \[66.25--66.75\]1 (50)1 (50)An et al., 2020 \[[@bib94]\]CT Manifestations of Novel Coronavirus Pneumonia: A Case Report[32157862](pmid:32157862){#intref0045}S3ChinaEnglishCase StudyAdult1500 (0)1 (100)Arentz et al., 2020 \[[@bib59]\]Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State[32191259](pmid:32191259){#intref0050}S4USAEnglishCohort StudyAdult2170 \[43--92\]11 (52)10 (48)Bai et al., 2020 \[[@bib128]\]Analysis of the first cluster of cases in a family of novel coronavirus pneumonia in Gansu Province[32064855](pmid:32064855){#intref0055}S5ChinaChineseCase seriesAdult753.43 (43)4 (57)Chan et al., 2020 \[[@bib4]\]A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster[31986261](pmid:31986261){#intref0060}S6_adultChinaEnglishCase seriesAdult550 \[36.25--64.50\]2 (40)3 (60)Chang et al., 2020 \[[@bib131]\]Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China[32031568](pmid:32031568){#intref0065}S7ChinaEnglishCohort StudyAdult1334 \[34--48\]10 (77)3 (33)Chen et al., 2020 \[[@bib95]\]Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia[32164089](pmid:32164089){#intref0070}S8ChinaChineseCohort StudyAdult2956 \[range 26--79\]21 (72)8 (28)Chen et al., 2020 \[[@bib67]\]Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19[32141280](pmid:32141280){#intref0075}S9_severeChinaChineseCohort StudyAdult (severe)2468.5 (13.6)18 (75)6 (25)Chen et al., 2020 \[[@bib67]\]Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19[32141280](pmid:32141280){#intref0080}S9_nonsevereChinaChineseCohort StudyAdult (non-severe)12657.1 (15.6)66 (52)60 (48)Chen et al., 2020 \[[@bib39]\]Clinical progression of patients with COVID-19 in Shanghai, China[32171869](pmid:32171869){#intref0085}S10ChinaEnglishCohort StudyAdult24951 \[36--64\]126 (51)123 (49)Chen et al., 2020 \[[@bib140]\]Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[32007143](pmid:32007143){#intref0090}S11ChinaEnglishCohort StudyAdult9955.5 (13.1)67 (68)32 (32)Chen et al., 2020 \[[@bib161]\]Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study[32217556](pmid:32217556){#intref0095}S12ChinaEnglishCohort StudyAdult27462 \[44--70\]171 (62)103 (38)Cheng et al., 2020 \[[@bib149]\]Epidemiological characteristics of novel coronavirus pneumonia in Henan[32118390](pmid:32118390){#intref0100}S13ChinaChineseCohort StudyAdult107946 \[IQR: 24\]573 (53)506 (47)Cheng et al., 2020 \[[@bib62]\]Clinical Features and Chest CT Manifestations of Coronavirus Disease 2019 (COVID-19) in a Single-Center Study in Shanghai, China[32174128](pmid:32174128){#intref0105}S14ChinaEnglishCohort StudyAdult1150.36 (15.5)8 (73)3 (27)Cheng et al., 2020 \[[@bib157]\]First case of Coronavirus Disease 2019 (COVID-19) pneumonia in Taiwan[32113824](pmid:32113824){#intref0110}S15TaiwanEnglishCase StudyAdult1550 (0)1 (100)[b](#tbl1fnb){ref-type="table-fn"} \[[@bib69]\]Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus Disease in South Korea[32149037](pmid:32149037){#intref0115}S16KoreaEnglishCohort StudyAdult2842.6 \[range 20--73\]15 (54)13 (46)Dai et al., 2020 \[[@bib105]\]CT Imaging and Differential Diagnosis of COVID-19[32129670](pmid:32129670){#intref0120}S17ChinaEnglishCase SeriesAdult450 \[47.75--55.125\]4 (100)0 (0)Deng et al., 2020 \[[@bib68]\]Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study[32209890](pmid:32209890){#intref0125}S18_deathChinaEnglishCohort StudyAdult and pediatric10969\[62--74\]73 (67)36 (33)Deng et al., 2020 \[[@bib68]\]Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study[32209890](pmid:32209890){#intref0130}S18_survivalChinaEnglishCohort StudyAdult and pediatric11640\[33--57\]51 (44)65 (56)Ding et al., 2020 \[[@bib72]\]The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China[32196707](pmid:32196707){#intref0135}S19ChinaEnglishCase SeriesAdult549 \[47--50\]2 (40)3 (60)Ding et al., 2020 \[[@bib28]\]A cured patient with 2019-nCoV pneumonia[32205073](pmid:32205073){#intref0140}S20ChinaEnglishCase StudyAdult1570 (0)1 (100)Dong et al., 2020 \[[@bib106]\]Epidemiological characteristics of confirmed COVID-19 cases in Tianjin[32164400](pmid:32164400){#intref0145}S21ChinaEnglishCohort StudyAdult13548.62 (16.83)72 (53)63 (47)Duan and Qin 2020 \[[@bib144]\]Pre- and Posttreatment Chest CT Findings - 2019 Novel Coronavirus (2019-nCoV) Pneumonia[32049602](pmid:32049602){#intref0150}S22ChinaEnglishCase StudyAdult1460 (0)1 (100)Fan et al., 2020 \[[@bib49]\]Perinatal Transmission of COVID-19 Associated SARS-CoV-2: Should We Worry?[32182347](pmid:32182347){#intref0155}S23ChinaEnglishCase SeriesAdult231.5 \[30.25--32.75\]0 (0)2 (100)Fang et al., 2020 \[[@bib93]\]Changes of CT findings in a 2019 novel coronavirus (2019-nCoV) pneumonia patient[32073631](pmid:32073631){#intref0160}S24ChinaEnglishCase StudyAdult1471 (100)0 (0)Fang et al., 2020 \[[@bib88]\]Comparisons of nucleic acid conversion time of SARS-CoV-2 of different samples in ICU and non-ICU patients[32209381](pmid:32209381){#intref0165}S25ChinaEnglishCohort StudyAdult324116 (50)16 (50)Fang et al., 2020 \[[@bib115]\]CT Manifestations of Two Cases of 2019 Novel Coronavirus (2019-nCoV) Pneumonia[32031481](pmid:32031481){#intref0170}S26ChinaEnglishCase SeriesAdult238.5 \[35.25--41.75\]1 (50)1 (50)Gautret et al., 2020 \[[@bib127]\]Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial[32205204](pmid:32205204){#intref0175}S27FranceEnglishCase SeriesAdult3647 \[24.5--61.5\]15 (42)21 (58)Gross et al., 2020 \[[@bib112]\]CT appearance of severe, laboratory-proven coronavirus disease 2019 (COVID-19) in a Caucasian patient in Berlin, Germany[32193883](pmid:32193883){#intref0180}S28GermanyEnglishCase StudyAdult1611 (100)0 (0)Guan et al., 2020 \[[@bib25]\]Epidemiological investigation of a family clustering of COVID-19[32149484](pmid:32149484){#intref0185}S29ChinaChineseCase SeriesAdult753.433 (43)4 (57)Guan et al., 2020 \[[@bib138]\]Clinical Characteristics of Coronavirus Disease 2019 in China[32109013](pmid:32109013){#intref0190}S30ChinaEnglishCohort StudyAdult109947 \[35--58\]639 (58)460 (42)Guan et al., 2020 \[[@bib142]\]CT Findings of Coronavirus Disease (COVID-19) Severe Pneumonia[32208010](pmid:32208010){#intref0195}S31ChinaEnglishCase StudyAdult1590 (0)1 (100)Guan et al., 2020 \[[@bib120]\]Imaging Features of Coronavirusdisease 2019 (COVID-19): Evaluationon Thin-Section CT[32204990](pmid:32204990){#intref0200}S32ChinaEnglishCohort StudyAdult5342 \[range 1--86\]25 (47)28 (53)Han et al., 2020 \[[@bib137]\]Early Clinical and CT Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia[32181672](pmid:32181672){#intref0205}S33ChinaEnglishCohort StudyAdult1084538 (35)70 (65)Han et al., 2020 \[[@bib104]\]The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019[32073161](pmid:32073161){#intref0210}S34ChinaEnglishCase StudyAdult1471 (100)0 (0)Hao, 2020 \[[@bib30]\]Clinical features of atypical 2019 novel coronavirus pneumonia with an initially negative RT-PCR assay[32092387](pmid:32092387){#intref0215}S35ChinaEnglishCase studyAdult1581 (100)0 (0)He et al., 2020 \[[@bib52]\]Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients[32171190](pmid:32171190){#intref0220}S36ChinaChineseCohort StudyAdult5468 \[59.8--74.3\]34 (63)20 (37)Hill et al., 2020 \[[@bib118]\]The index case of SARS-CoV-2 in Scotland: a case report[32205138](pmid:32205138){#intref0225}S37ScotlandEnglishCase StudyAdult1511 (100)0 (0)Holshue et al., 2020 \[[@bib113]\]First Case of 2019 Novel Coronavirus in the United States[32004227](pmid:32004227){#intref0230}S38USAEnglishCase StudyAdult1351 (100)0 (0)Hosoda et al., 2020 \[[@bib57]\]SARS-CoV-2 enterocolitis with persisting to excrete the virus for about two weeks after recovering from diarrhea: A case report[32188528](pmid:32188528){#intref0235}S39JapanEnglishCase StudyAdult1810 (0)1 (100)Hu et al., 2020 \[[@bib119]\]Clinical characteristics of 24 asymptomatic infections with COVID19 screened among close contacts in Nanjing, China[32146694](pmid:32146694){#intref0240}S40ChinaEnglishCohort StudyAdult2432.5 \[19.0--57.0\]8 (33)16 (64)Hu et al., 2020 \[[@bib102]\]CT imaging of two cases of one family cluster 2019 novel coronavirus (2019-nCoV) pneumonia: inconsistency between clinical symptoms amelioration and imaging sign progression[32190575](pmid:32190575){#intref0245}S41ChinaEnglishCase SeriesAdult242.5 \[40.25--44.75\]1 (50)1 (50)Huang et al., 2020 \[[@bib76]\]Clinical characteristics of laboratory confirmed positive cases of SARS-CoV2 infection in Wuhan, China: A retrospective single center analysis[32114074](pmid:32114074){#intref0250}S42ChinaEnglishCohort StudyAdult3456.24 (17.14)14 (41)20 (59)Huang et al., 2020 \[[@bib66]\]Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[31986264](pmid:31986264){#intref0255}S43ChinaEnglishCohort StudyAdult4149 \[41--58\]30 (73)11 (27)Huang et al., 2020 \[[@bib109]\]Use of Chest CT in Combination with Negative RT-PCR Assay for the 2019 Novel Coronavirus but High Clinical Suspicion[32049600](pmid:32049600){#intref0260}S44ChinaEnglishCase StudyAdult1361 (100)0 (0)Jin et al., 2020 \[[@bib63]\]Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms[32213556](pmid:32213556){#intref0265}S45_withGIChinaEnglishCohort StudyAdult - with GI Symptoms7446.14 (14.19)37 (50)37 (50)Jin et al., 2020 \[[@bib63]\]Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms[32213556](pmid:32213556){#intref0270}S45_noGIChinaEnglishCohort StudyAdult - No GI Symptoms57745.09 (14.45)294 (51)283 (49)Lee et al., 2020 \[[@bib54]\]A case of COVID-19 and pneumonia returning from Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG dynamic[32198005](pmid:32198005){#intref0275}S46VietnamEnglishCase studyAdult1460 (0)1 (100)Leung et al., 2020 \[[@bib47]\]Clinical features of deaths in the novel coronavirus epidemic in China[32175637](pmid:32175637){#intref0280}S47ChinaEnglishCohort StudyAdult4670.6 (12.63)31 (67)15 (33)Li et al., 2020 \[[@bib114]\]CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19)[32215691](pmid:32215691){#intref0285}S48ChinaEnglishCohort StudyAdult7844.6 (17.9)38 (49)40 (51)Li et al., 2020 \[[@bib99]\]Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19[32114745](pmid:32114745){#intref0290}S49ChinaChineseCohort StudyAdult1046.5 \[36.5--64.3\]5 (50)5 (50)Li et al., 2020 \[[@bib96]\]Comparison of epidemic characteristics between SARS in 2003 and COVID-19 in 2020 in Guangzhou[32159317](pmid:32159317){#intref0295}S50ChinaChineseCohort StudyAdult34648 \[range 3 months--90 yo\]167 (48)179 (52)Li et al., 2020 \[[@bib111]\]Comparison of the clinical characteristics between RNA positive and negative patients clinically diagnosed with 2019 novel coronavirus pneumonia[32087623](pmid:32087623){#intref0300}S51ChinaChineseCohort StudyAdult315415 (48)16 (52)Lian et al., 2020 \[[@bib77]\]Analysis of Epidemiological and Clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan[32211844](pmid:32211844){#intref0305}S52_youngChinaEnglishCohort StudyAdult (young and middle-aged \< 60 years)65241.15 (1.38)349 (54)303 (46)Lian et al., 2020 \[[@bib77]\]Analysis of Epidemiological and Clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan[32211844](pmid:32211844){#intref0310}S52_oldChinaEnglishCohort StudyAdult (elderly\>=60 years)13668.28 (7.31)58 (43)78 (57)Lin et al., 2020 \[[@bib40]\]Novel coronavirus pneumonia outbreak in 2019: Computed tomographic findings in two cases[32056397](pmid:32056397){#intref0315}S53ChinaEnglishCase SeriesAdult237 \[36--38\]2 (100)0 (0)Liu et al., 2020 \[[@bib147]\]Clinical feature of COVID-19 in elderly patients: a comparison with young and middle-aged patients[32171866](pmid:32171866){#intref0320}S54_oldChinaEnglishCohort StudyAdult (elderly\>=60 years)1868.00 \[65.25--69.75\]12 (67)6 (33)Liu et al., 2020 \[[@bib147]\]Clinical feature of COVID-19 in elderly patients: a comparison with young and middle-aged patients[32171866](pmid:32171866){#intref0325}S54_youngChinaEnglishCohort StudyAdult (young and middle-aged \< 60 years)3847 \[35.75--51.25\]19 (50)19 (50)Liu et al., 2020 \[[@bib153]\]Gross examination of report of a COVID-19 death autopsy[32198987](pmid:32198987){#intref0330}S55ChinaChineseCase StudyAdult1851 (100)0 (0)Liu et al., 2020 \[[@bib90]\]Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia[32062957](pmid:32062957){#intref0335}S56ChinaChineseCohort StudyAdult3035 \[21--59\]10 (33)20 (67)Liu et al., 2020 \[[@bib81]\]Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease[32118640](pmid:32118640){#intref0340}S57ChinaEnglishCohort StudyAdult7838 \[33--57\]39 (50)39 (50)Liu et al., 2020 \[[@bib74]\]Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury[32048163](pmid:32048163){#intref0345}S58_adultChinaEnglishCase SeriesAdult1263 \[53.5--65\]8 (67)4 (33)Liu et al., 2020 \[[@bib133]\]Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province.[32044814](pmid:32044814){#intref0350}S59ChinaEnglishCohort StudyAdult13757 \[range 20--83\]61 (45)76 (55)Liu et al., 2020 \[[@bib146]\]Clinical and CT imaging features of the COVID-19 pneumonia: Focus on pregnant women and children[32171865](pmid:32171865){#intref0355}S60_adultChinaEnglishCohort StudyAdult1433.5 \[range 27-58\]5 (36)9 (64)Mo et al., 2020 \[[@bib98]\]Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China[32173725](pmid:32173725){#intref0360}S61ChinaEnglishCohort StudyAdult15554 \[42--66\]86 (55)69 (45)Pan et al., 2020 \[[@bib132]\]Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China[32055945](pmid:32055945){#intref0365}S62ChinaEnglishCohort StudyAdult6344.9 (15.2)33 (52)30 (48)Peng et al., 2020 \[[@bib145]\]Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nVoC[32120458](pmid:32120458){#intref0370}S63_severeChinaChineseCohort StudyAdult (severe)1657.5 \[54--63\]9 (56)7 (44)Peng et al., 2020 \[[@bib36]\]Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nVoC[32120458](pmid:32120458){#intref0375}S63_nonsevereChinaChineseCohort StudyAdult (non-severe)9662 \[55--67.5\]44 (46)52 (54)Qian et al., 2020 \[[@bib80]\]A COVID-19 Transmission within a family cluster by presymptomatic infectors in China[32201889](pmid:32201889){#intref0380}S64_adultChinaEnglishCase seriesAdult757.5 \[44.5--59\]3 (43)4 (57)Qian et al., 2020 \[[@bib156]\]Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series[32181807](pmid:32181807){#intref0385}S65ChinaEnglishCohort StudyAdult9150 \[36.5--57\]37 (41)54 (59)Qu et al., 2020 \[[@bib61]\]Platelet‐to‐lymphocyte ratio is associated with prognosis in patients with coronavirus disease‐19[32181903](pmid:32181903){#intref0390}S66ChinaEnglishCohort StudyAdult3050.5 \[36--65\]16 (53)14 (47)Ren et al., 2020 \[[@bib165]\]Identification of a novel coronavirus causing severe pneumonia in human - a descriptive study[32004165](pmid:32004165){#intref0395}S67ChinaEnglishCase SeriesAdult552 \[49--61\]3 (60)2 (40)Ruan et al., 2020 \[[@bib130]\]A case of 2019 novel coronavirus infected pneumonia with twice negative 2019-nCoV nucleic acid testing within 8 days[32149771](pmid:32149771){#intref0400}S68ChinaEnglishCase studyAdult1470 (0)1 (100)Shi et al., 2020 \[[@bib44]\]Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China[32211816](pmid:32211816){#intref0405}S69ChinaEnglishCohort StudyAdult41664 \[range 21--90\]205 (49)211 (51)Shi et al., 2020 \[[@bib51]\]Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study[32105637](pmid:32105637){#intref0410}S70ChinaEnglishCohort StudyAdult8149.5 (11)42 (52)39 (48)Shi et al., 2020 \[[@bib103]\]Evolution of CT Manifestations in a Patient Recovered from 2019 Novel Coronavirus (2019-nCoV) Pneumonia in Wuhan, China[32032497](pmid:32032497){#intref0415}S71ChinaEnglishCase StudyAdult1421 (100)0 (0)Silverstein et al., 2020 \[[@bib91]\]First imported case of 2019 novel coronavirus in Canada, presenting as mild pneumonia[32061312](pmid:32061312){#intref0420}S72CanadaEnglishCase StudyAdult1561 (100)0 (0)Song et al., 2020 \[[@bib60]\]SARS-CoV-2 induced diarrhea as onset symptom in patient with COVID-19[32139552](pmid:32139552){#intref0425}S73ChinaEnglishCase StudyAdult1221 (100)0 (0)Song et al., 2020 \[[@bib164]\]Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia[32027573](pmid:32027573){#intref0430}S74ChinaEnglishCohort StudyAdult5149 (16)25 (49)26 (51)Spiteri et al., 2020 \[[@bib31]\]First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020[32156327](pmid:32156327){#intref0435}S75EuropeEnglishCohort StudyAdult3842 \[range 2--81\]25 (66)13 (34)Stoecklin et al., 2020 \[[@bib160]\]First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020[32070465](pmid:32070465){#intref0440}S76FranceEnglishCase SeriesAdult331 \[30.5--39.5\]2 (67)1 (33)Sun et al., 2020 \[[@bib134]\]Epidemiological and Clinical Predictors of COVID-19[32211755](pmid:32211755){#intref0445}S77SingaporeEnglishCohort StudyAdult5442 \[34--54\]29 (54)25 (46)Sun et al., 2020 \[[@bib89]\]Evolution of Computed Tomography Manifestations in Five Patients Who Recovered from Coronavirus Disease 2019 (COVID-19) Pneumonia.[32174054](pmid:32174054){#intref0450}S78ChinaEnglishCase SeriesAdult545 \[range 20--55\]2 (40)3 (60)Tang et al., 2020 \[[@bib108]\]Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia[32073213](pmid:32073213){#intref0455}S79ChinaEnglishCohort StudyAdult18354.1 (16.2)98 (54)85 (46)Tian et al., 2020 \[[@bib148]\]Characteristics of COVID-19 infection in Beijing[32112886](pmid:32112886){#intref0460}S80ChinaEnglishCohort StudyAdult26247.5 \[range 1--94\]127 (48)135 (52)Tian et al., 2020 \[[@bib84]\]Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer[32114094](pmid:32114094){#intref0465}S81_case1ChinaEnglishCase StudyAdult1731 (100)0 (0)Tian et al., 2020 \[[@bib84]\]Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer[32114094](pmid:32114094){#intref0470}S81_case2ChinaEnglishCase StudyAdult1840 (0)1 (100)Tong et al., 2020 \[[@bib38]\]Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020[32091386](pmid:32091386){#intref0475}S82ChinaEnglishCase SeriesAdult623.00 \[15.00--41.75\]3 (50)3 (50)Van Cuong et al., 2020 \[[@bib154]\]The first Vietnamese case of COVID-19 acquired from China[32085849](pmid:32085849){#intref0480}S83VietnamEnglishCase StudyAdult1250 (0)1 (100)Wan et al., 2020 \[[@bib70]\]Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing[32198776](pmid:32198776){#intref0485}S84ChinaEnglishCohort StudyAdult13547 \[36--55\]72 (53)63 (47)Wang et al., 2020 \[[@bib56]\]Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment[32037389](pmid:32037389){#intref0490}S85ChinaEnglishCase seriesAdult447.5 \[28.75--63\]3 (75)1 (25)Wang et al., 2020 \[[@bib139]\]Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China[32031570](pmid:32031570){#intref0495}S86ChinaEnglishCohort StudyAdult13856 \[42--68\]75 (54)63 (46)Wang et al., 2020 \[[@bib100]\]Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China[32176772](pmid:32176772){#intref0500}S87ChinaEnglishCohort StudyAdult6942 \[35--62\]32 (46)37 (54)Wang et al., 2020 \[[@bib45]\]Clinical Outcomes in 55 Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Who Were Asymptomatic at Hospital Admission in Shenzhen, China[32179910](pmid:32179910){#intref0505}S88ChinaEnglishCohort StudyAdult5549 \[range 2--69\]22 (40)33 (60)Wang et al., 2020 \[[@bib26]\]The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China[32139464](pmid:32139464){#intref0510}S89ChinaEnglishCohort StudyAdult1839 \[29--55\]10 (56)8 (44)Wu et al., 2020 \[[@bib125]\]Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study[32109279](pmid:32109279){#intref0515}S90ChinaEnglishCohort StudyAdult8046.1(15.42)39 (49)41 (51)Wu et al., 2020 \[[@bib85]\]Biological characters analysis of COVID-19 patient accompanied with aplastic anemia[32145715](pmid:32145715){#intref0520}S91ChinaChineseCase StudyAdult1481 (100)0 (0)Xie et al., 2020 \[[@bib82]\]Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests[32114193](pmid:32114193){#intref0525}S92ChinaEnglishCase SeriesAdult934 \[26--45\]4 (44)5 (56)Xiong et al., 2020 \[[@bib50]\]Clinical and High-Resolution CT Features of the COVID-19 Infection: Comparison of the Initial and Follow-up Changes[32134800](pmid:32134800){#intref0530}S93ChinaEnglishCohort StudyAdult4249.5 (14.1)25 (60)17 (40)Xu et al., 2020 \[[@bib73]\]Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2[32109443](pmid:32109443){#intref0535}S94ChinaEnglishCohort StudyAdult5043.9 (16.8)29 (58)21 (42)Xu et al., 2020 \[[@bib22]\]Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2[32107577](pmid:32107577){#intref0540}S95ChinaEnglishCohort StudyAdult9050 \[range 18--86\]39 (43)51 (57)Xu et al., 2020 \[[@bib64]\]Pathological findings of COVID-19 associated with acute respiratory distress syndrome[32085846](pmid:32085846){#intref0545}S96ChinaEnglishCase StudyAdult1501 (100)0 (0)Xu et al., 2020 \[[@bib8]\]Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series[32075786](pmid:32075786){#intref0550}S97ChinaEnglishCohort StudyAdult6241 \[32--52\]35 (56)27 (44)Xu et al., 2020 \[[@bib41]\]Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19[32179140](pmid:32179140){#intref0555}S98_importedChinaEnglishCohort StudyAdult153510 (67)5 (33)Xu et al., 2020 \[[@bib41]\]Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19[32179140](pmid:32179140){#intref0560}S98_secondaryChinaEnglishCohort StudyAdult17377 (41)10 (59)Xu et al., 2020 \[[@bib41]\]Clinical features and dynamics of viral load in imported and non-importedpatients with COVID-19[32179140](pmid:32179140){#intref0565}S98_tertiaryChinaEnglishCohort StudyAdult19538 (42)11 (58)Yang et al., 2020 \[[@bib126]\]Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China[32112884](pmid:32112884){#intref0570}S99ChinaEnglishCohort StudyAdult14945.11 (13.35)81 (54)68 (46)Yang et al., 2020 \[[@bib9]\]Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study[32105632](pmid:32105632){#intref0575}S100ChinaEnglishCohort StudyAdult5259.7 (13.3)35 (67)17 (33)Yao et al., 2020 \[[@bib42]\]Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region[32153170](pmid:32153170){#intref0580}S101ChinaChineseCohort StudyAdult4053.87 (15.84)25 (63)15 (37)Yao et al., 2020 \[[@bib143]\]Epidemiological characteristics of 2019-ncoV infections in Shaanxi, China by February 8, 2020[32139462](pmid:32139462){#intref0585}S102ChinaEnglishCohort StudyAdult19544.13 (15.8)129 (66)66 (34)Ye et al., 2020 \[[@bib23]\]Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation[32171867](pmid:32171867){#intref0590}S103ChinaEnglishCase seriesAdult531 \[30--32\]2 (40)3 (60)Yoon et al., 2020 \[[@bib141]\]Chest Radiographic and CT Findings of the 2019 Novel Coronavirus Disease (COVID-19): Analysis of Nine Patients Treated in Korea[32100485](pmid:32100485){#intref0595}S104South KoreaEnglishCohort StudyAdult9544 (44)5 (56)Young et al., 2020 \[[@bib79]\]Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore[32125362](pmid:32125362){#intref0600}S105SingaporeEnglishCohort StudyAdult1847 \[31--71\]9 (50)9 (50)Yu et al., 2020 \[[@bib150]\]A Familial Cluster of Infection Associated With the 2019 Novel Coronavirus Indicating Possible Person-to-Person Transmission During the Incubation Period[32067043](pmid:32067043){#intref0605}S106ChinaEnglishCase seriesAdult472 \[68--78.25\]2 (50)2 (50)Yuan et al., 2020 \[[@bib55]\]Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China[32191754](pmid:32191754){#intref0610}S107ChinaEnglishCohort StudyAdult2760 \[47--69\]12 (44)15 (56)Zhang et al., 2020 \[[@bib71]\]CT image of novel coronavirus pneumonia: a case report[32189175](pmid:32189175){#intref0615}S108ChinaEnglishCase StudyAdult1641 (100)0 (0)Zhang et al., 2020 \[[@bib27]\]Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing[32164091](pmid:32164091){#intref0620}S109ChinaChineseCohort StudyAdult936 \[15--49\]5 (56)4 (44)Zhang et al., 2020 \[[@bib34]\]Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China[32077115](pmid:32077115){#intref0625}S110ChinaEnglishCohort StudyAdult14057 \[range 25--87\]71 (51)69 (49)Zhang et al., 2020 \[[@bib155]\]Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings.[32205284](pmid:32205284){#intref0630}S111ChinaEnglishCohort StudyAdult57346.65 (13.83)295 (51)278 (49)Zhang et al., 2020 \[[@bib117]\]High-resolution CT features of 17 cases of Corona Virus Disease 2019 in Sichuan province, China[32139463](pmid:32139463){#intref0635}S112ChinaEnglishCohort StudyAdult1748.6 \[range 23--74\]8 (47)9 (53)Zhao et al., 2020 \[[@bib162]\]The characteristics and clinical value of chest CT images of novel coronavirus pneumonia[32199619](pmid:32199619){#intref0640}S113ChinaEnglishCohort StudyAdult8044 (1.77)43 (54)37 (46)Zhao et al., 2020 \[[@bib78]\]A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias[32161968](pmid:32161968){#intref0645}S114ChinaEnglishCohort StudyAdult1948 \[27--56\]11 (58)8 (42)Zhou et al., 2020 \[[@bib48]\]Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study[32171076](pmid:32171076){#intref0650}S115ChinaEnglishCohort StudyAdult19156 \[46.0--67.0\]119 (62)72 (38)Zhu et al., 2020 \[[@bib110]\]Comparison of heart failure and 2019 novel coronavirus pneumonia in chest CT features and clinical characteristics[32129583](pmid:32129583){#intref0655}S116ChinaChineseCohort StudyAdult1252 \[32--73\]8 (67)4 (33)Zhu et al., 2020 \[[@bib58]\]Clinical and CT imaging features of 2019 novel coronavirus disease (COVID-19)[32142928](pmid:32142928){#intref0660}S117ChinaEnglishCase SeriesAdult643 \[32--56\]0 (0)6 (100)[^3][^4]Table 2Included studies of pregnant women with COVID-19.Table 2**AuthorsTitlePMIDUnique study IDCountryLanguageStudy typeStudy populationSample sizeAge**[a](#tbl2fna){ref-type="table-fn"}Male (%)**Female (%)**Chen et al., 2020 \[[@bib29]\]Pregnant women with new coronavirus infection: a clinical characteristics and placental pathological analysis of three cases[32114744](pmid:32114744){#intref0665}S118ChinaChineseCase SeriesPregnant329.60 (0)3 (100)Chen et al., 2020 \[[@bib75]\]Chest computed tomography images of early coronavirus disease (COVID-19)[32162211](pmid:32162211){#intref0670}S119ChinaEnglishCase StudyPregnant1270 (0)1 (100)Chen et al., 2020 \[[@bib11]\]Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records[32151335](pmid:32151335){#intref0675}S120ChinaEnglishCase seriesPregnant928 \[26--33\]0 (0)9 (100)Dong et al., 2020 \[[@bib46]\]Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn[32215581](pmid:32215581){#intref0680}S121_pregnantChinaEnglishCase StudyPregnant1290 (0)1 (100)Liao et al., 2020 \[[@bib122]\]Chest CT Findings in a Pregnant Patient with 2019 Novel Coronavirus Disease[32212578](pmid:32212578){#intref0685}S122ChinaEnglishCase StudyPregnant1250 (0)1 (100)Liu et al., 2020 \[[@bib146]\]Clinical and CT imaging features of the COVID-19 pneumonia: Focus on pregnant women and children[32171865](pmid:32171865){#intref0690}S60_pregnantChinaEnglishCohort StudyPregnant1630 \[26--35\]0 (0)16 (100)Wang et al., 2020 \[[@bib123]\]A case of 2019 Novel Coronavirus in a pregnant woman with preterm delivery[32119083](pmid:32119083){#intref0695}S123ChinaEnglishCase studyPregnant1280 (0)1 (100)Wang et al., 2020 \[[@bib152]\]A case report of neonatal COVID-19 infection in China[32161941](pmid:32161941){#intref0700}S124_pregnantChinaEnglishCase studyPregnant1340 (0)1 (100)Wen at al, 2020 \[[@bib124]\]A patient with SARS-CoV-2 infection during pregnancy in Qingdao, China[32198004](pmid:32198004){#intref0705}S125ChinaEnglishCase studyPregnant1310 (0)1 (100)Xia et al., 2020 \[[@bib136]\]Emergency Caesarean delivery in a patient with confirmed coronavirus disease 2019 under spinal anaesthesia[32192711](pmid:32192711){#intref0710}S126ChinaEnglishCase StudyAdult1270 (0)1 (100)[^5]Table 3Included studies of pediatric and neonatal patients with COVID-19Type a message.Table 3AuthorsTitlePMIDUnique study IDCountryLanguageStudy typeStudy populationSample sizeAge[a](#tbl3fna){ref-type="table-fn"}Male (%)Female (%)Cai et al., 2020 \[[@bib65]\]First case of 2019 novel coronavirus infection in children in Shanghai[32102141](pmid:32102141){#intref0715}S127ChinaChineseCase StudyPediatric171 (100)0 (0)Chan et al., 2020 \[[@bib4]\]A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster[31986261](pmid:31986261){#intref0720}S6_pediatricChinaEnglishCase seriesPediatric1101 (100)0 (0)Chen et al., 2020 \[[@bib101]\]First case of severe childhood novel coronavirus pneumonia in China[32135586](pmid:32135586){#intref0725}S128ChinaChineseCase StudyPediatric11.11 (100)0 (0)Cui et al., 2020 \[[@bib33]\]A 55-Day-Old Female Infant Infected With 2019 Novel Coronavirus Disease: Presenting With Pneumonia, Liver Injury, and Heart Damage[32179908](pmid:32179908){#intref0730}S129ChinaEnglishCase studyNeonatal155 (days)0 (0)1 (100)Dong et al., 2020 \[[@bib46]\]Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn[32215581](pmid:32215581){#intref0735}S121_pediatricChinaEnglishCase StudyNeonatal100 (0)1 (100)Dong et al., 2020 \[[@bib92]\]Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China[https://doi.org/10.1542/peds.2020-0702](10.1542/peds.2020-0702){#intref0740}S130ChinaEnglishCohort StudyPediatric73110 \[2--13\]420 (57)311 (43)Fan et al., 2020 \[[@bib158]\]Anal swab findings in an infant with COVID-19DOI: 10.1002/ped4.12186S131ChinaEnglishCase StudyNeonatal10.250 (0)1 (100)Feng et al., 2020 \[[@bib87]\]Analysis of CT features of 15 children with 2019 novel coronavirus infection[32061200](pmid:32061200){#intref0745}S132ChinaChineseCase seriesPediatric157 \[range 4--14\]5 (33)10 (67)Ji et al., 2020 \[[@bib135]\]Clinical features of pediatric patients with COVID-19: a report of two family cluster cases[32180140](pmid:32180140){#intref0750}S133ChinaEnglishCase SeriesPediatric212.0 \[10.5--13.5\]2 (100)0 (0)Le et al., 2020 \[[@bib24]\]The first infant case of COVID-19 acquired from a secondary transmission in Vietnam[32213326](pmid:32213326){#intref0755}S134VietnamEnglishCase StudyNeonatal10.250 (0)1 (100)Liu et al., 2020 \[[@bib74]\]Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury[32048163](pmid:32048163){#intref0760}S58_pediatricChinaEnglishCase StudyPediatric1101 (100)0 (0)Liu et al., 2020 \[[@bib86]\]Detection of Covid-19 in Children in Early January 2020 in Wuhan, China[32163697](pmid:32163697){#intref0765}S135ChinaEnglishCase SeriesPediatric63 \[3--3.75\]2 (33)4 (67)Liu et al., 2020 \[[@bib146]\]Clinical and CT imaging features of the COVID-19 pneumonia: Focus on pregnant women and children[32171865](pmid:32171865){#intref0770}S60_pediatricChinaEnglishCohort StudyPediatric43.0 \[0.7--6.0\]2 (50)2 (50)Lu et al., 2020 \[[@bib37]\]SARS-CoV-2 Infection in Children[32187458](pmid:32187458){#intref0775}S136ChinaEnglishCohort StudyPediatric1716.7 \[2--9.8\]104 (61)67 (39)Park et al., 2020 \[[@bib163]\]First Pediatric Case of Coronavirus Disease 2019 in Korea[32193905](pmid:32193905){#intref0780}S137South KoreaEnglishCase StudyPediatric1100 (0)1 (100)Qian et al., 2020 \[[@bib80]\]A COVID-19 Transmission within a family cluster by presymptomatic infectors in China[32201889](pmid:32201889){#intref0785}S64_pediatricChinaEnglishCase studyPediatric (asymptomatic)11.10 (0)1 (100)Sun et al., 2020 \[[@bib116]\]Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center\'s observational study[32193831](pmid:32193831){#intref0790}S138ChinaEnglishCase seriesPediatric810.2 \[5.04--13.54\]6 (75)2 (25)Tang et al., 2020 \[[@bib43]\]Detection of Novel Coronavirus by RT-PCR in Stool Specimen from Asymptomatic Child, China[32150527](pmid:32150527){#intref0795}S139ChinaEnglishCase StudyPediatric1101 (100)0 (0)Wang et al., 2020 \[[@bib83]\]SARS-CoV-2 infection with gastrointestinal symptoms as the first manifestation in a neonate[32204755](pmid:32204755){#intref0800}S140ChinaChineseCase StudyNeonatal119 (days)1 (100)0 (0)Wang et al., 2020 \[[@bib152]\]A case report of neonatal COVID-19 infection in China[32161941](pmid:32161941){#intref0805}S124_pediatricChinaEnglishCase studyNeonatal101 (100)0 (0)Wang et al., 2020 \[[@bib107]\]Clinical analysis of 31 cases of 2019 novel coronavirus infection in children from six provinces (autonomous region) of northern China[32118389](pmid:32118389){#intref0810}S141ChinaChineseCohort StudyPediatric317.1 \[0.6--17\]15 (48)16 (52)Wei et al., 2020 \[[@bib53]\]Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China[32058570](pmid:32058570){#intref0815}S142ChinaEnglishCase SeriesNeonatal90.58 \[0.33--0.75\]2 (22)7 (78)Xia et al., 2020 \[[@bib151]\]Clinical and CT features in pediatric patients with COVID-19 infection:\
Different points from adults[32134205](pmid:32134205){#intref0820}S143ChinaEnglishCohort StudyPediatric202 \[range 1 day--14 years 7 months\]13 (65)7 (35)Xu et al., 2020 \[[@bib35]\]Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral sheddingPMCID: PMC7095102S144ChinaEnglishCase SeriesPediatric106.63 \[2.17--13.4\]6 (60)4 (40)Zeng et al., 2020 \[[@bib97]\]First case of neonate infected with novel coronavirus pneumonia in China[32065520](pmid:32065520){#intref0825}S145ChinaChineseCase StudyNeonatal117 (days)1 (100)0 (0)Zhang et al., 2020 \[[@bib145]\]2019-novel coronavirus infection in a three-month-old baby[32043842](pmid:32043842){#intref0830}S146ChinaChineseCase studyNeonatal10.250 (0)1 (100)Zheng et al., 2020 \[[@bib129]\]Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China[32207032](pmid:32207032){#intref0835}S147ChinaEnglishCohort StudyPediatric253 \[2--9\]14 (56)11 (44)Zhou et al., 2020 \[[@bib121]\]Clinical features and chest CT findings of coronavirus disease 2019 in infants and young children[32204756](pmid:32204756){#intref0840}S148ChinaChineseCase SeriesPediatric91 \[range 7 months-3 years\]4 (44)5 (56)[^6]

In terms of study population, 114 studies included only adult participants, 6 only pregnant women, 22 only children and neonates, and 6 included mixed cohorts. Of the total 12′149 patients included, 6′410 (52.8%) were male and 5′739 were female (47.2%, [Fig. 2](#fig2){ref-type="fig"} A and B). The median age of adult (11′058 patients, 91.0%), pregnant (35 patients, 0.3%), and pediatric (1′056 patients, 8.7%; including neonates) patients was 47.0 years \[35.0--65.3\] ([Fig. 3](#fig3){ref-type="fig"} A), 30.0 \[26.0--33.0\] ([Fig. 3](#fig3){ref-type="fig"}B), and 10.0 \[2.0--13.0\] ([Fig. 3](#fig3){ref-type="fig"}C), respectively. Approximately 7.8% (297/3′822 patients) were reported to be asymptomatic and 7.7% (617/8′047) died during hospitalization due to complications related to the infection with SARS-CoV-2. With the exception of one 10-month old child, all deaths were non-pregnant adult COVID-19 patients.Fig. 2Proportion of female and male patients in adult (A) and pediatric/neonatal cohort (B). All case studies/reports were pooled together for visualization (CS_adult, and CS_children \[pediatric/neonatal\]). The key to the study identifier can be found in [Table 1](#tbl1){ref-type="table"} (adults) and [Table 3](#tbl3){ref-type="table"} (children).Fig. 2Fig. 3Age of adult (A), pregnant (B), and pediatric/neonatal COVID-19 patients (C) included in eligible studies. Median age and interquartile ranges (IQR) are represented by the midpoints and error bars, respectively. The studies have been sorted by patients\' median age in years. The size of the midpoint (circle, square, triangle) indicates the study sample size. The red line represents the pooled median age of the respective cohort. All adult case studies/reports (CS_adult) were pooled for the visualization reasons. The key to the study identifier can be found in [Table 1](#tbl1){ref-type="table"} (adults), [Table 2](#tbl2){ref-type="table"} (pregnant women), and [Table 3](#tbl3){ref-type="table"} (children). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 3

3.2. Adult patients {#sec3.2}
-------------------

Higher proportions of male than female patients were reported to be infected with SARS-CoV-2 (t = 2.678, df = 202, p = 0.008; [Fig. 2](#fig2){ref-type="fig"}A) across all studies. Comorbidities were present in \~31% of the adult patients (2′329/7′608), with hypertension being the most prevalent one (1′352/6′460 patients, 20.93%), followed by heart failure (37/354 patients, 10.5%), diabetes mellitus (678/6′535 patients, 10.4%), and coronary heart disease (194/2′388 patients, 8.5%) ([Fig. 4](#fig4){ref-type="fig"} A, [Table 4](#tbl4){ref-type="table"} , [Supplementary Fig. 1](#appsec1){ref-type="sec"}). The most frequent clinical signs and symptoms were fever (6′955/8′859 patients, 78.5%), cough (4′778/8′885 patients, 53.8%), and fatigue (1′996/7′980 patients, 25.0%) ([Fig. 4](#fig4){ref-type="fig"}B, [Table 4](#tbl4){ref-type="table"}). A little over five percent of the adult COVID-19 patients were asymptomatic (148/2′749 patients, 5.4%). Over 6′969 patients (89.6%) had abnormal CT imaging features. The most common patterns of CT abnormalities were indicating pneumonia (unilateral or bilateral; 6′620/7′917 patients, 83.6%), including air bronchogram (264/523 patients, 50.5%), and ground-glass opacity (GGO) with consolidation (153/323 patients, 47.4%) and without (2′446/5′591 patients, 43.8%) ([Table 4](#tbl4){ref-type="table"}, [Supplementary Fig. 2](#appsec1){ref-type="sec"}). In terms of laboratory parameters, inflammatory markers, such as interleukin 6 (22 pg/mL \[4.68--51.8\]), and erythrocyte sedimentation rate (32.5 mm/h \[17.3--53.8\]) were elevated across the adult population. Moreover, markers of coagulation, namely D-dimer (0.5 μg/mL \[0.3--1.08\]), fibrinogen (4.5 g/L \[3.66--5.1\]), and cell damage were also elevated (i.e., lactate dehydrogenase, U/L; 213 \[173--268\]). An overview of all laboratory parameters is provided in [Supplementary Table 4](#appsec1){ref-type="sec"}. As shown in [Fig. 4](#fig4){ref-type="fig"}D, the most common treatments were antivirals (4′475/6′068 patients, 73.8%), oxygen therapy (1′300/1′872 patients, 69.4%), and antibiotics (2′518/4′825 patients, 52.2%). Detailed information on all treatments is provided in [Table 4](#tbl4){ref-type="table"}. Eight percent (616/7′727 patients) of the adults died during the hospitalization due to complications related to COVID-19. Amongst the survivors (7′111/7′727 patients, 92.0%), a total of 3′025 (68.7%) remained hospitalized, 1′751 (32.4%) were discharged, and 1′012 (27.1%) reportedly recovered ([Fig. 4](#fig4){ref-type="fig"}C, [Table 4](#tbl4){ref-type="table"}). Important to note, for some patients it was stated that they both, recovered and were discharged (i.e., one patient can fall in multiple categories). The median duration between symptoms onset and hospitalization was 8 days \[7--9.5\]. A total of 195 (6.8%) patients were admitted to the intensive care unit (ICU). The most frequently reported complications associated with COVID-19 were pneumonia (1′032/1′489 patients, 69.2%), respiratory failure (141/413 patients, 34.1%), acute cardiac injury (242/1′250 patients, 19.4%), and ARDS (759/5′122 patients, 14.8%), ([Fig. 4](#fig4){ref-type="fig"}D, [Table 4](#tbl4){ref-type="table"}).Fig. 4Comorbidities (A), clinical signs and symptoms (B), outcomes (C), and treatments administered (D) to adult COVID-19 patients. The colors indicated the proportion of patients (%, 0 = yellow, 100 = dark purple). Note: Missing values are colored in white. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 4Table 4Summary for random-effects models for prevalence of comorbidities, clinical signs and symptoms, imaging features, treatments, outcomes and complications in adult CoVID-19 patients.Table 4VariableNumber of studiesPatientsTotal patientsCrude prevalence \[%\]Random- effects models (REM) PrevalenceREM (lower CI)REM (upper CI)*T*^2^*I*^2^Q**Comorbidities**Any comorbidity852′3297′60830.6129.5724.0835.711.27195.4902.92Hypertension581′3526′46020.9323.2419.2327.80.58590.4517.13Diabetes mellitus536786′53510.3711.8110.1213.720.21870.0187.38Carcinoma361116′0331.842.151.562.950.44756.795.51Chronic obstructive pulmonary disease29865′2321.641.700.923.11.97684.5147.80Cardiovascular disease281803′7474.806.094.049.101.01485.0208.10Chronic kidney disease20563′5211.591.850.933.631.53679.484.55Coronary heart disease171942′3888.129.324.5318.212.16794.3294.63Any liver disease15515808.793.851.449.892.21583.595.23Cerebrovascular disease131122′5684.363.952.127.231.02587.5143.74Current smoker132663′4007.825.794.327.720.15668.862.4Hepatitis B12542′3332.721.415.160.72471.534.60Chronic liver disease11952′5763.693.693.034.490015.53Any respiratory system disease10491′0204.802.951.286.671.04578.845.62Heart failure53735410.4520.122.2573.365.88595.643.48Immunodeficiency564181.441.620.1812.83.88981.319.40**Clinical signs and symptoms**Asymptomatic691482′7495.380.40.072.2111.53593.6664.40Patients reported with any sign or symptom651′9362′59774.5598.0392.4899.519.12396.2864.92Fever1106′9558′85978.5182.9679.1386.210.96891.61′096.03Cough1024′7788′88553.7858.3853.9262.700.52890.11′671.74Fatigue691′9967′98025.0129.2524.0335.070.91894.21′140.98Diarrhea584656′4757.188.326.6310.40.49776.9343.2Sore throat497266′53811.1013.0410.016.840.68388.7357.51Sputum481′4376′11823.4925.0619.6831.350.85094.3904.12Headache487107′5649.3910.48.2912.970.51186.0326.48Chest tightness468854′59619.2624.2117.0233.211.73795.3882.92Myalgia468085′28415.2918.9914.6924.190.77990.7411.98Dyspnea397055′73012.3015.2010.5421.431.44694.8881.01Nausea313295′3616.147.064.8710.110.83788.0211.11Running nose (rhinorrhea)251132′5134.507.304.5711.460.67671.3115.97Nasal congestion202194′4874.889.324.717.652.08994.7166.83Dizziness or confusion18971′0549.2013.66.9224.971.37684.885.04Hemoptysis13653′2981.972.371.623.440.17044.223.26Anorexia102051′20217.0514.217.325.841.13293.9131.95Emesis or vomiting6388574.434.433.246.04004.42Chest pain6648327.697.782.9718.861.38990.890.01Abdominal pain7387405.145.112.938.770.22346.222.04**Imaging features**Pathologic findings936′9697′78089.5897.8395.3899.005.93497.4952.20Pneumonia936′6207′91783.6296.8793.7198.475.88598.11′610.32Ground glass opacity (GGO)622′4465′59143.7569.1356.7479.272.90097.91′126.68Bilateral pneumonia482′7454′24764.6377.2970.0883.171.17394.6931.56Unilateral pneumonia327993′74521.3419.2716.4622.430.15473.086.28Consolidation307712′02238.1338.3326.9451.161.26592.1271.44GGO with consolidation1515332347.3749.5340.3558.730.17443.126.58Local patchy shadowing84241′16136.5235.7915.6462.631.42675.428.40Bilateral patchy shadowing125771′34143.0356.1523.5884.161.65992.658.37Nodular lesions13701′3455.2015.397.3129.551.33983.393.73Air bronchogram1026452350.4849.4341.5957.290.12959.523.29Pleural effusion10526667.817.885.0412.110.29255.624.46Reticulation/interlobular septal thickening7811′2446.5121.885.1059.344.46795.8296.72Interstitial abnormalities5163115814.0821.3910.8837.750.41970.420.65Crazy paving pattern55921028.1030.7513.8955.000.69075.226.42**Treatments**Antiviral treatment574′4756′06873.7592.7485.6596.475.03198.42′064.73Antibiotics472′5184′82552.1974.9454.3888.247.24499.02′226.02Corticosteroids341′7155′82829.4339.0827.2452.372.18598.11′647.19All mechanical ventilation328075′22815.4429.2416.4246.513.96398.31′248.53Invasive mechanical ventilation252383′5066.798.844.3916.972.96995.6356.53High flow nasal cannula201′2982′74547.2947.3927.9367.672.65498.3499.24Non-invasive mechanical ventilation235023′83813.0814.238.6022.651.65096.1590.79Intravenous immunoglobin207813′16224.7021.6715.4729.500.07094.0486.21Alpha interferon aerosol inhalation1536774549.2689.4155.0198.316.31397.4331.79Lopinavir195101′28439.7287.5456.5297.448.61898.4428.93Ritonavir195101′28439.7287.5456.5297.448.61898.4428.93Oxygen therapy2013001′87269.4483.8372.7690.961.51995.2406.24Extracorporeal membrane oxygenation22314′6510.670.510.161.634.51786.993.79Oseltamivir134431′15938.2296.3941.4299.99.26991.889.74Renal replacement therapy18624′5721.361.350.483.784.01092.7154.71Immune enhancing treatment510325440.5586.2125.1799.157.82796.11′96.76Antifungal treatment5701′5164.626.813.6812.280.40181.732.66**Outcomes**Death996167′7277.971.280.542.998.55997.01′806.30Survived997′1117′72792.0398.7297.0199.468.55997.01′806.30Discharged561′7515′40132.4252.1535.2568.585.25798.52′161.24Remained hospitalized483′0254′40568.6766.9953.2778.323.00897.61′440.97Recovery341′0123′74127.0553.7632.3573.875.49598.51′685.14**Complications**Admission to intensive care unit231952′8776.789.685.4116.731.68591.4314.57Acute respiratory distress syndrome277595′12214.8222.9712.6937.943.12198.01321.27Shock181404′2913.262.411.105.222.26793.0301.37Acute kidney injury182414′1135.867.173.7513.281.88995/0335.95Acute cardiac injury132421′25019.3613.548.5820.720.63188.2109.82All secondary infections11626309.849.736.1115.150.35858.930.69Respiratory failure814141334.1429.9411.2858.952.22492.5108.36Pneumonia71′0311′48969.24338.3672.684.6798.2476.86Secondary infections (bacteria)552022.482.481.035.81009.06Heart failure69158915.4510.342.7432.072.25494.843.99

3.3. Pregnant woman {#sec3.3}
-------------------

Studies investigating the effect of COVID-19 in pregnant women reported that only five pregnant women had any history of comorbidities. Hypothyroidism, allergies, or influenza were reported each for one pregnant woman (in two cases the exact nature of comorbidity was not reported) ([Supplementary Table 5](#appsec1){ref-type="sec"}). Fever (25/35 patients, 71.4%), cough (12/29 patients, 41.4%), and myalgia (3/9 patients, 33.3%) were the three most common symptoms observed in pregnant women that were infected with SARS-CoV-2 ([Supplementary Fig. 3](#appsec1){ref-type="sec"}, [Supplementary Table 5](#appsec1){ref-type="sec"}). Abnormal CT features were evident in 88.6% (31/35 patients) of pregnant women diagnosed with COVID-19. Pneumonia (unilateral or bilateral, 31/35 patients, 88.6%), GGO (29/34 patients, 85.3%), and consolidation (8/16 patients, 50.0%) were among the most common patterns of CT abnormalities ([Supplementary Fig. 4](#appsec1){ref-type="sec"}, [Supplementary Table 5](#appsec1){ref-type="sec"}). Inflammatory markers, such as C-reactive protein (19.25 mg/L \[12.35--25.7\]), procalcitonin (0.187 ng/mL), and neutrophil count (9.14 × 10^9^/L) were elevated in this patient population. Along this line, lactate dehydrogenase concentrations were increased (544 U/L) reflecting cellular damage. An overview of all laboratory parameters is provided in [Supplementary Table 4](#appsec1){ref-type="sec"}. Moreover, antibiotics (14/14 patients, 100.0%), antivirals (11/14 patients, 78.6%) and oxygen therapy (high flow nasal cannula; 3/12 patients, 25.0%) were used to treat pregnant COVID-19 patients ([Supplementary Table 5](#appsec1){ref-type="sec"}). None of the pregnant COVID-19 patients died. Lastly, one patient was admitted to the ICU ([Supplementary Table 5](#appsec1){ref-type="sec"}).

3.4. Pediatric and neonatal patients {#sec3.4}
------------------------------------

Similar to the adult cohort, the proportion between female and male patients were comparable in the pediatric/neonatal cohort (t = 1.169, df = 26, p = 0.253; [Fig. 2](#fig2){ref-type="fig"}B). Fourteen percent of the children and neonates were asymptomatic (149/1′054). With the exception of two children, no comorbidities were reported for any of the pediatric or neonatal patients ([Supplementary Table 6](#appsec1){ref-type="sec"}). Similar to the adult and pregnant COVID-19 patients, children and neonates frequently presented with fever (170/320 patients, 53.1%), cough (149/311 patients, 47.9%), and sputum (14/51 patients, 27.5%) ([Supplementary Fig. 6](#appsec1){ref-type="sec"} and [Supplementary Table 6](#appsec1){ref-type="sec"}). Sixty-five percent of the pediatric and neonatal patients presented with CT abnormalities, including pneumonia (194/298 patients), GGO (108/278 patients, 38.9%), and local patchy shadowing (52/223 patients, 23.3%) ([Supplementary Fig. 7](#appsec1){ref-type="sec"}, [Supplementary Table 6](#appsec1){ref-type="sec"}). An overview of all laboratory parameters is provided in [Supplementary Table 7](#appsec1){ref-type="sec"}. As the reference values vary considerably within the pediatric/neonatal patient population, the results of the laboratory parameters have to be interpreted with caution. In terms of treatment, children and neonates received antibiotics (31/43 patients, 72.1%), oxygen therapy through high flow nasal cannula (5/9 patients, 55.6%), and alpha interferon aerosol inhalation therapy (31/52, 59.6%) to treat COVID-19 and its complications ([Supplementary Fig. 8](#appsec1){ref-type="sec"}, [Supplementary Table 6](#appsec1){ref-type="sec"}). With the exception of a 10-month-old child that died four weeks after admission of multi-organ failure, all children survived. Less than 30% remained hospitalized (90/293 patients), 74.5% were discharged (216/290 patients) and 87.4% reportedly recovered (236/270 patients) ([Supplementary Fig. 9](#appsec1){ref-type="sec"}, [Supplementary Table 6](#appsec1){ref-type="sec"}). The median duration between symptoms onset and hospitalization was 6 days \[4.0--8.5\]. Fifteen percent (6/39 patients) had to be admitted to the ICU. Complications associated with COVID-19 comprised pneumonia (16/26 patients, 61.5%), secondary bacterial infection (12/21 patients, 57.1%), and respiratory failure (10/33 patients, 30.3%) ([Supplementary Table 6](#appsec1){ref-type="sec"}).

3.5. Non-severe vs. severe {#sec3.5}
--------------------------

Twelve studies (2′596 patients) provided separate data for patients with a severe (500 patients, 19.3%) and non-severe disease status (2′096, 80.7%). No differences regarding sex were found between severe (t = 0.604, df = 16.645, p = 0.554; male: 278 patients \[55.6%\] and female: 210 patients \[42.0%\]; unknown sex: 12 patients \[2.4%\]) and non-severe disease status group (t = 0.217, df = 16.393, p = 0.831; male: 1′059 patients \[50.5%\] and female: 925 patients \[49.5%\]) ([Supplementary Fig. 10](#appsec1){ref-type="sec"}). In terms of age, patients with non-severe COVID-19 were significantly younger (median age in years = 45.0 \[34.0--57.0\]) than those with a severe disease progression (61.4 \[44.5--75.5\], [Fig. 5](#fig5){ref-type="fig"} ). Our meta-analysis revealed that older age (SMD: 0.68 \[0.40--0.97\]; p \< 0.001), being male (RR = 1.11 \[1.01--1.22\]; p = 0.039), and preexisting comorbidities (RR = 2.11 \[1.02--4.35\], p = 0.046) were associated with a higher risk of increased disease severity. Specifically, hypertension (RR = 2.15 \[1.64--2.81\], p \< 0.001), diabetes mellitus (RR = 2.56 \[1.50--4.39\], p = 0.005), any heart condition (RR = 4.09 \[2.45--6.84\], p \< 0.001), and chronic obstructive pulmonary disease (COPD, RR = 5.10 \[3.08--8.45\], p \< 0.001) ([Fig. 6](#fig6){ref-type="fig"} , [Table 5](#tbl5){ref-type="table"} ) were associated with worse outcome (i.e., severe disease). To test if the increased risk of heart conditions is attributable to the study that has classified their patients into severe and non-severe based on the presence or absence of cardiac injuries, we conducted a sensitivity analysis excluding this study \[[@bib44]\]. The risk of any heart condition remained significantly elevated in the severe disease patient cohort (RR = 3.87 \[1.85--8.11\], p = 0.005). Numerous laboratory parameters were significantly different between the non-severe and severe patient cohorts. Patients with severe disease status presented with decreased levels of albumin (SMD = 1.60 \[-2.97 - (−0.24)\]; p = 0.022), hemoglobin (SMD = −0.23 \[-0.41- (−0.06)\]; p = 0.001), and thrombocytes (SMD = −0.57 \[-0.68-(-0.45)\]; p \< 0.001) in comparison to patients with non-severe disease status. Additionally, C-reactive protein (SMD = 1.47 \[0.88--2.07\]; p \< 0.001), lactate dehydrogenase (SMD = 1.71 \[1.08--2.34\]; p \< 0.001), and aspartate transaminase levels (SMD = 0.85 \[0.61--1.09\]; p \< 0.001) were elevated in patients with severe disease status. In terms of complications, patients with severe COVID-19 disease were at an elevated risk of developing ARDS (RR = 10.59 \[2.44--46.01\], p = 0.014, [Fig. 6](#fig6){ref-type="fig"}). The heterogeneity between the studies varied substantially ([Table 5](#tbl5){ref-type="table"}). Publication bias, measured by means of the Egger\'s test, was only evident in three analyses. However, Egger\'s test may lack the statistical power to detect bias when the number of studies is small (i.e., fewer than 10) as we only included 4--8 studies.Fig. 5Age of non-severe (A), severe (B), survivor (C), and non-survivor (D) COVID-19 patients included in eligible studies. The median age and Interquartile ranges (IQR) are represented by the midpoints and error bars, respectively. The studies have been sorted by patients\' median age in years. The size of the midpoint indicates the study sample size. The red line indicates the pooled median age of the respective cohort. The key to the study identifier can be found in [Table 1](#tbl1){ref-type="table"}. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 5Fig. 6Relative risks of comorbidities (i.e., hypertension, diabetes mellitus, and COPD) and complications (i.e., ARDS) in patients with a severe COVID-19 disease progression. Funnel plots indicate the potential of publication bias. The key to the study identifier can be found in [Table 1](#tbl1){ref-type="table"}.Fig. 6Table 5Results of meta-analyses for patients with severe and non-severe disease outcomes as well as survivors and non-survivors.Table 5Number of StudiesNumber of events/Number of severeNumber of events/Number of non-severeRR \[95% CI\]p-value*T*^*2*^*I*^*2*^Cochranes QEgger\'s test (p-value)Severe (cases) vs non-severe CoVID-19 disease (controls)**Demographics**Sex: male10278/4881059/19871.11 \[1.01--1.22\]0.0390.0040%7.670.763Sex: female10210/488925/19870.95 \[0.82--1.10\]0.4500.00618.6%11.050.395Age114872059SMD: 0.68 \[0.40--0.97\]\<0.0010.15481.8%55.050.012**Comorbidities**Any comorbidity4167/307291/12052.11 \[1.02--4.35\]0.0460.16079.8%14.860.122Hypertension8158/429292/17342.15 \[1.64--2.81\]\<0.0010.01835.8%10.910.664Diabetes mellitus784/427127/17202.56 \[1.50--4.39\]0.0050.03849.7%11.920.279Any heart condition764/42758/17204.09 \[2.45--6.84\]\<0.0010.03222.7%7.760.548Chronic obstructive pulmonary disease (COPD)623/40315/15945.10 \[3.08--8.45\]\<0.00100%1.590.034Carcinoma515/34519/15123.13 \[0.63--15.64\]0.1200.69642.9%7.000.339**Symptoms and signs**Fever8399/4621588/18471.02 \[0.99--1.06\]0.187\<0.00141.3%11.920.644Fatigue8199/462611/18471.21 \[0.99--1.48\]0.0590.00446.0%12.950.011Myalgia553/318237/14541.01 \[0.66--1.56\]0.929\<0.00120.7%5.040.702Headache747/404187/17651.14 \[0.94--1.39\]0.146\<0.0010.0%1.650.625Cough8290/4621051/18471.14 \[1.02--1.27\]0.0260.00615.1%8.250.633Sputum685/385384/15491.05 \[0.79--1.39\]0.460\<0.00114.8%5.870.873Dyspnea691/20756/5874.67 \[0.99--21.91\]0.0501.15676.2%21.030.148Sore throat/Pharyngalgia641/358182/15491.40 \[0.62--3.17\]0.3370.21850.9%10.190.831Diarrhea641/40377/15941.76 \[0.72--4.32\]0.1640.29653.7%10.800.384**Treatment**Antibiotics4254/309743/14101.63 \[0.67--3.96\]0.1770.28593.5%45.930.807Antiviral treatment6249/347888/15261.05 \[0.90--1.22\]0.4900.01177.7%22.450.604Corticosteroids5200/345416/15122.26 \[1.32--3.87\]0.0140.17493.7%63.660.211**Imaging features (i.e., CT)**Pathological findings7400/4161372/16311.06 \[0.96--1.18\]0.1920.00990.1%60.320.085Pneumonia5373/3891290/15391.05 \[0.94--1.18\]0.2990.00892.1%50.580.176**Complications**Acute respiratory distress symptom (ARDS)4117/33165/145710.59 \[2.44--46.01\]0.0140.60684.1%18.900.067Acute kidney injury416/3318/14576.60 \[0.37--116.33\]0.1282.07565.0%8.560.909**Laboratory parameterNumber of studiesNumber of severeNumber of non-severeSMD \[95% CI\]p-value*T***^*2*^***I***^*2*^**Cochranes QEgger\'s test (p-value)**Albumin3131511−1.60 \[-2.97 - (−0.24)\]0.0221.38596%50.010.790Alanine aminotransferase (ALT)61846950.27 \[0.06--0.47\]0.0110.01422.1%6.420.545Aspartate transaminase (AST)61846950.85 \[0.61--1.09\]\<0.0010.03136.5%7.880.942Creatinine62057940.59 \[0.12--1.07\]0.0150.29887.3%39.300.501C-reactive protein (CRP)62277741.47 \[0.88--2.07\]\<0.0010.48791.2%56.500.296D-dimer41433610.55 \[0.22--0.89\]0.0010.06659.4%7.390.632Hemoglobin63421618−0.23 \[-0.41- (−0.06)\]0.0010.01637.2%7.960.927Lactate dehydrogenase (LDH)4932791.71 \[1.08--2.34\]\<0.0010.29477.3%13.200.599Leucocytes741216760.49 \[-0.24-1.21\]0.1870.90597.0%202.830.175Lymphocytes84151703−0.59 \[-0.88 - (−0.30)\]\<0.0010.11879.1%33.540.986Monocytes359239−0.10 \[-0.39- 0.19\]0.51900%0.580.180Neutrophils4993340.94 \[0.27--1.61\]0.0060.38485.6%20.80.409Potassium43041437−0.21 \[-0.40 - (−0.02)\]0.0340.01541.2%5.10.502Procalcitonin41945660.72 \[0.06--1.38\]0.0320.41092.0%37.550.848Sodium43041437−0.26 \[-0.67-0.15\]0.2010.13786.3%21.970.533Thrombocytes73571621−0.57 \[-0.68-(-0.45)\]\<0.00100.0%3.470.127**Others**Time since onset of symptoms to admission52367890.14 \[-0.12- 0.41\]0.2910.05664.8%11.360.465**Number of StudiesNumber of events/Number of non-survivorsNumber of events/Number of survivorsRR \[95% CI\]p-value*T***^***2***^***I***^***2***^**Cochranes QEgger\'s test (p-value)**Non-survivors (cases) vs survivors (controls)**Demographics**Sex: male7236/340326/6171.32 \[1.13--1.54\]0.0050.00221.8%7.670.700Sex: female7104/340291/6170.65 \[0.53--0.83\]0.00501.6%6.100.540Age7340617SMD: 1.25 \[0.78--1.72\]\<0.0010.29485.7%41.970.012**Comorbidities**Any comorbidity6207/308234/5971.69 \[1.48--1.94\]\<0.001012.910.115Hypertension5125/28790/4352.09 \[1.65--2.64\]0.001\<0.0010%2.080.545Diabetes mellitus571/31853/4511.88 \[1.26--2.81\]0.012\<0.0010%2.880.141Any heart condition548/31815/4513.95 \[1.03--15.20\]0.047.47745.5%7.350.666Cerebrovascular disease312/1550/19836.88 \[8.50--160.04\]0.00900%0.070.305Any lung disease439/30814/4343.03 \[0.61--15.04\]0.115.42949.8%5.970.811Carcinoma512/3188/4512.26 \[0.67--7.61\]0.13600%2.840.020Current smoker413/20013/3222.02 \[0.61--6.72\]0.160\<0.0010%2.650.136**Symptoms and signs**Fever6288/319407/4551.00 \[ 0.95--1.05\]0.97400%4.90.022Fatigue3109/276129/4141.24 \[ 1.14--1.36\]0.00900%0.090.991Myalgia535/21066/3390.97 \[ 0.61--1.55\]0.8950.0260%3.140.385Headache419/25529/3010.83 \[0.64--1.09\]0.12000%0.260.930Cough6196/319196/4551.37 \[ 0.58--3.24\]0.3850.60592.3%64.860.389Sputum484/27793/4181.43 \[0.65--3.15\]0.2450.18262.4%7.990.886Dyspnea4178/26485/3142.60 \[ 0.58--11.65\]0.1370.56186%21.490.611Diarrhea348/27771/4180.96 \[0.38--2.43\]0.8600.07727.6%2.760.838**Treatment**Antibiotics5280/309395/4381.03 \[0.99--1.07\]0.11400%2.090.293Antiviral treatment5222/329446/5960.94 \[0.79--1.13\]0.4260.00667.7%12.380.260Corticosteroids4229/308227/4341.29 \[0.66--2.54\]0.3210.13680.6%15.440.873Immunoglobulin4143/308122/4341.88 \[0.36--9.69\]0.3090.97992.5%40.230.213Oxygen nasal (high flow)4154/308139/4342.16 \[0.09--50.50\]0.4933.84398.1%158.980.030All mechanical ventilation5298/319115/4556.05 \[1.41--26.05\]0.0261.12684.5%25.750.686Non-invasive mech. ventilation5181/30945/4385.33 \[1.52--18.71\]0.0210.56566.7%12.020.765Invasive mech. ventilation589/3095/43814.14\[138--145.09\]0.0342.08059.7%9.920.181Renal replacement therapy422/2001/32210.36 \[0.98--110.07\]0.0510.1940%1.920.057Extracorporeal membrane oxygenation512/3092/4384.39 \[1.64--11.78\]0.01400%1.350.033**Imaging features (i.e, CT)**Pathological findings6562/577325/3350.97 \[0.87--1.09\]0.5880.00675.9%20.710.675Pneumonia3159/168254/3021.07 \[0.97--1.17\]0.089\<0.0010%1.340.680**Complications**ARDS6298/319115/4554.24 \[1.30--13.83\]0.0261.11592.8%69.920.197Shock498/2770/418242.79 \[23.70--2487.07\]0.00500%0.640.300Acute cardiac injury4178/30823/43413.21 \[0.70--248.38\]0.0682.78381.8%16.480.435Acute kidney injury588/3095/43520.77 \[2.43--177.44\]0.0172.30167.7%12.370.229**Laboratory parameterNumber of StudiesNumber of casesNumber of controlsSMD \[95% CI\]p-value*T***^*2*^***I***^*2*^**Cochranes QEgger\'s test (p-value)**[a](#tbl5fna){ref-type="table-fn"}Albumin2110120−1.14 \[-1.41 -- (−0.85)\]\<0.00100%0n.a.ALT32232810.45 \[0.08--0.82\]0.0160.05662.7%6.370.984AST21141650.17 \[-0.07 -- 0.41\]0.16800%0.76n.a.Creatinine4200s3222.24 \[-0.56 -- 5.03\]0.1177.71998.8%244.970.460CRP21141650 \[-0.24 -- 0.24\]1.000%0n.a.D-dimer41742741.54 \[-0.17 -- 3.25\]0.0772.37096.8%94.990.672Hemoglobin3142140−0.08 \[-0.32 -- 0.16\]0.50400%0.610.610LDH21101201.61 \[1.31--1.91\]\<0.00100%0.3n.a.Leucocytes42774182.21 \[0.61--3.64\]0.0061.98997.9%144.570.421Lymphocytes4255301−0.92 \[-1.3 -- (−0.55)\]\<0.0010.07964.6%8.47Neutrophils2551413.6 \[3.12--4.08\]\<0.00100%0.17n.a.Potassium2551410.41 \[0.1--0.77\]0.0100%0.01n.a.Thrombocytes41962770.9 \[-2.09 -- 3.88\]0.5568.91699%309.320.487Partial thromboplastin time (PTT)52062947.99 \[4.64--11.34\]\<0.00113.24598.9%370.170.194Activated partial thromboplastin time (APTT)36515821.73 \[4.34--39.13\]0.014231.93399.5%363.820.386Interleukin 6 (IL-6)21101201.21 \[0.93--1.5\]\<0.00100%0.44n.a.**Others**Time since onset of symptoms to admission31952730.47 \[-0.09 -- 1.02\]0.0980.20185.8%14.050.797[^7]

3.6. Survivor vs. non-survivors {#sec3.6}
-------------------------------

Seven studies (957 patients) provided disaggregated data for COVID-19 survivors (617 patients, 64.5%) and non-survivors (340, 35.5%). No differences regarding sex were found in the survivor group (t = 0.258, df = 11.879, p = 0.801; male: 326 patients \[52.8%\] and female: 291 patients \[47.2%\]), but a significantly higher proportion of male patients were amongst the deceased cohort (t = 4.30, df = 12, p = 0.001; male: 236 patients \[69.4%\] and female: 104 patients \[30.6%\]) ([Supplementary Fig. 10](#appsec1){ref-type="sec"}). In terms of age, COVID-19 patients that survived were significantly younger (median age in years = 52.0 \[35.0--66.0\]) than non-survivors (68.0 \[62.0--76.0\], [Fig. 5](#fig5){ref-type="fig"}). The meta-analysis yielded older age (SMD: 1.25 \[0.78--1.72\]; p \< 0.001), being male (RR = 1.32 \[1.13--1.54\], p = 0.005), and pre-existing comorbidities (RR = 1.69 \[1.48--1.94\]; p \< 0.001) as potential risk factors of in-hospital mortality. Pre-existing cerebrovascular diseases (RR = 36.88 \[8.50--160.04\]; p = 0.009), heart conditions (RR = 3.95 \[1.03--15.20\], p = 0.047, [Fig. 7](#fig7){ref-type="fig"} A), and hypertension (RR = 2.09 \[1.65--2.64\]; p = 0.001) were found to be associated with the highest risks of mortality. Clinical signs and symptoms as well as imaging features were comparable between survivors and non-survivors. In terms of treatments, non-survivors were more frequently mechanically ventilated than survivors (RR = 6.05 \[1.41--26.05\]; p = 0.026, [Fig. 7](#fig7){ref-type="fig"}B) and more commonly received extracorporeal membrane oxygenation (RR = 4.39 \[1.64--11.78\], p = 0.014). Non-survivors had higher risks of complications, particularly acute kidney injury (RR = 20.77 \[2.43--177.44\], p = 0.017; [Fig. 7](#fig7){ref-type="fig"}C) and ARDS (RR = 4.24 \[1.30--13.83\], p = 0.026, [Fig. 7](#fig7){ref-type="fig"}D). Low levels of albumin (SMD = −1.13 \[-1.41 -- (−0.85)\]; p \< 0.001) and lymphocytes (SMD = −0.92 \[-1.3 -- (−0.55)\]; p \< 0.001) as well as elevated level of interleukin 6 (SMD = 1.21 \[0.93--1.5\]; p \< 0.001), leucocytes (SMD = 2.21 \[0.61--3.64\]; p = 0.06), and prolonged prothrombin time (SMD = 7.99 \[4.64--11.34\]; p \< 0.01) were associated with death ([Table 5](#tbl5){ref-type="table"}). Publication bias, measured by means of the Egger\'s test, was only evident in five analyses.Fig. 7Relative risks of comorbidity (i.e., any heart condition), treatment (i.e., mechanical ventilation), and complications (i.e., acute kidney injury and ARDS) in survivors and non-survivors. Funnel plots indicate the potential of publication bias. The key to the study identifier can be found in [Table 1](#tbl1){ref-type="table"}.Fig. 7

4. Discussion {#sec4}
=============

As of May 1st, 2020, more than 3.3 million confirmed cases of COVID-19 and more than 230′000 deaths attributable to the disease, have been reported worldwide \[[@bib166],[@bib167]\]. In-depth knowledge of clinical, laboratory, and imaging factors that are associated with the disease progression and outcome is critical to inform clinical decision making and pandemic preparedness initiatives. An ever-growing number of research studies have been performed, but thus far the meta-analytical evidence is sparse. To address this paucity, we conducted a systematic review and meta-analysis of 148 studies involving over 12′000 patients providing an unprecedently comprehensive overview of comorbidities, clinical signs and symptoms, laboratory parameters, CT imaging features, treatment, outcomes, and complications in adult, pregnant, and pediatric/neonatal COVID-19 patients. Approximately eight percent of the patients were reported to be asymptomatic. However, this low number does not appear to reflect the reality as the vast majority of the included studies primarily reported on symptomatic patients and were not designed to screen for asymptomatic patients. Furthermore, over seven percent died from complications associated with COVID-19. Recent analysis suggests that up to 75% of the coronavirus infections caused no illness \[[@bib168], [@bib169], [@bib170]\]. Presumably, the virus has been circulating for longer than generally believed and large swathes of the population have already been exposed. Although our fatality rate lies within previous estimates \[[@bib171],[@bib172]\], it is important to mention that only a limited number of studies reported on the outcomes of COVID-19 (i.e., death, survival, recovery) and thus, caution has to be exercised when interpreting this number. Through our meta-analysis, we revealed several important risk factors that are associated with severe disease progression and mortality. Among these risk factors were two demographic factors, namely older age and being male. Well-studied consequences of ageing are the decline in the immune function (e.g., T-cell and B-cell function) and excess production of type 2 cytokines \[[@bib173],[@bib174]\]. These age-dependent changes in the immune response are suspected to cause deficiency in control of viral replication and more prolonged proinflammatory responses, potentially leading to poor outcome \[[@bib175]\]. Corroborative evidence stems from preclinical studies that found an age-dependent host innate responses to virus infection in non-human primates inoculated with SARS-CoV-1 \[[@bib176]\]. Confirming previous findings \[[@bib177],[@bib178]\], sex-specific differences in mortality and vulnerability to the disease were evident in the current study. Specifically, men were disproportionately affected by an infection with SARS-CoV-2 (i.e., proportion of men presented with COVID-19 was larger compared to women) and the in-hospital mortality amongst male patients was significantly higher compared to female patients. Emerging evidence pinpoints towards differences in the immune system \[[@bib140]\], genetic polymorphism \[[@bib179]\], life style factors including smoking \[[@bib180]\], personal hygiene habits \[[@bib181]\], pre-existing comorbidities \[[@bib182],[@bib183]\], and expression of angiotensin-converting enzyme 2 (ACE2) \[[@bib184],[@bib185]\] as potential explanations for the increased vulnerability in men. This sex difference in vulnerability has also been observed for SARS-CoV-1 and MERS \[[@bib186]\], two previously emerging coronavirus diseases. The lack of sex-disaggregated data in the reviewed studies made it impossible to further explore these potential explanations for the discrepant findings in men and women. Overall, the preexisting comorbidities, namely hypertension, diabetes mellitus, and any heart condition, were found to be linked with both, more severe diseases status and increased in-hospital mortality. Smoking, by contrast, was not associated with disease severity or mortality. However, the low number of studies reporting smoking status (13/148) cautions against early assumptions. Clinical signs and symptoms were comparable between patients with non-severe and severe COVID-19 as well as survivors and non-survivors. Fever, cough, and myalgia were amongst the most frequent reported symptoms across all groups. Similarly, the present study revealed no differences in the CT imaging features. The majority of the COVID-19 patients presented with pneumonia (bilateral or unilateral) and GGO. These pathological findings are a hallmark of any viral pneumonia, and thus it is not surprising that asymptomatic patients had similar distinctive features \[[@bib187]\]. In terms of laboratory parameters, elevated levels of interleukin 6, leucocytes, D-dimer, and lactate dehydrogenase as well as hypoalbuminemia and lymphopenia were more commonly seen in patients with severe COVID-19 illness and non-survivors. High levels of D-dimer have a reported association with 28-day mortality in patients with infections or sepsis admitted to the intensive care unit \[[@bib188]\]. Systemic pro-inflammatory cytokine responses (e.g., interleukin 6 and other components) contribute to host defense against infections, such as SARS-CoV-2 \[[@bib189], [@bib190], [@bib191]\]. However, exaggerated synthesis of interleukin 6 can lead to an acute, severe systemic inflammatory response syndrome (SIRS) known as 'cytokine storm' \[[@bib192]\]. In addition to SIRS, hypoalbuminemia and lymphopenia were previously shown to be associated with increased odds of severe infection and infection-related death \[[@bib193], [@bib194], [@bib195]\]. Complications were very common amongst patients with severe COVID-19 disease (over 50%) and non-survivors (more than two thirds). Acute cardiac injury, ARDS, and acute kidney injury were strongly linked to the outcomes. Widely used treatments for COVID-19 and associated complications comprised antibiotics, antivirals, and oxygen therapy. Patients with severe COVID-19 disease required more often mechanical ventilation and renal replacement therapy compared to those with non-severe COVID-19. Moreover, corticosteroids have been commonly administered to hospitalized patients with severe illness, although their benefit is highly disputed. Evidence from MERS or influenza suggests that patients who were given corticosteroids had prolonged viral replication, receive mechanical ventilation, and have higher mortality \[[@bib196], [@bib197], [@bib198], [@bib199]\]. Administration of antibiotics and antivirals was independent of disease-severity.

Pregnant women as well as pediatric and neonatal patients may be less vulnerable to complications of COVID-19. Comorbidities were almost non-existent in these patient cohorts. Clinical signs and symptoms, laboratory parameters, imaging features, and treatments were comparable to the adult (non-pregnant) cohort. While there was a considerable proportion of children and neonates with SARS-CoV-2 infections reported, most of these patients did not need hospitalization and recovered quite well. With the exception of a 10-month old neonate, no children were amongst the deaths reported. All pregnant women included in our study survived COVID-19 and associated complications.

4.1. Limitations of review {#sec4.1}
--------------------------

A limitation of the current review was that literature search was limited to articles listed in EMBASE, PubMed/Medline, Scopus, Web of Science, or identified by hand searches. Considering the pace at which the research in this area is moving forward, it is likely that the findings of the publications described in this paper will be quickly complemented by further research. The literature search also excluded grey literature (e.g., preprints, reports, conference proceedings), the importance of which to this topic is unknown, and thus might have introduced another source of search bias. There is also a probability of publication bias, as well as potential for a search bias. Publication bias is likely to result in studies with more positive results being preferentially submitted and accepted for publication. Moreover, geographical bias cannot be ruled out as the majority of the studies (129/148) were conducted in China. While symptoms might be quite comparable across countries, comorbidities, treatments, and outcomes potentially depend on the country (and its healthcare system). There is also a considerable risk for a reporting bias towards comorbidities, clinical signs and symptoms, laboratory parameters, imaging features, treatment, outcomes, and complications that are present. Specifically, only a minority of studies reported a zero when this information was assessed, but absent in patients. Lack of data on absent clinical signs and symptoms might lead to distorted estimates of proportion. Furthermore, the low number of asymptomatic patients must be considered with caution. The meta-analysis of severity and mortality could only be performed with a small number of studies as the minority of the 148 provided data separately for different disease severity groups (e.g., non-severe, severe, survivors, non-survivors). This needs to be considered when interpreting the results, including the publication bias as the Egger\'s test may lack the statistical power to detect bias when the number of studies is small (i.e., \<10). Lastly, the criteria to classify patients in severe and non-severe COVID-19 disease cohorts varied between studies leading to additional heterogeneity between studies. By virtue of low number of studies available, we could not assess this heterogeneity nor adjust for it.

4.2. Conclusion and future directions {#sec4.2}
-------------------------------------

In conclusion, this unprecedentedly comprehensive systematic review and meta-analysis of the literature published during the first 120 days of the COVID-19 pandemic yields important information regarding the comorbidities, clinical signs and symptoms, laboratory parameters, imaging features, treatment, outcomes, and complications. Male sex, older age, and pre-existing comorbidities are major risk factors for in-hospital mortality and complications. This study revealed a fatality rate of 7.7% and found that approximately 8% of the patients were reportedly asymptomatic. Based on recent reports, the latter number is likely 6- to 10-fold higher as only a few asymptomatic patients are captured by the health care system as they do not seek medical attention due to the lack of symptoms \[[@bib168]\] or are not hospitalized and thus, included in studies. Unnoticed asymptomatic cases of COVID-19 are likely a major source of ongoing transmission. Children and neonates appear to be the least vulnerable cohort. Forthcoming studies are needed that provide sex-disaggregated data to better characterize risk factors that affect both sexes or are specific to men or women, respectively.
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